TVGNHIGH SIGNALFINANCIAL10-K

TVGN shows severe financial deterioration with net losses nearly doubling to $26.3M while current assets collapsed 35% to just $1.5M, creating acute liquidity concerns.

The company faces an immediate cash crisis with severely depleted current assets of only $1.5M against $7.1M in current liabilities, creating negative working capital of $5.6M. Despite R&D spending cuts of 64%, losses still worsened dramatically, indicating fundamental operational challenges beyond normal development costs.

Comparing 2026-03-31 vs 2025-04-02View on EDGAR →
FINANCIAL ANALYSIS

TVGN's financial position deteriorated sharply with net losses expanding 91% to $26.3M despite slashing R&D expenses by 64% to $11.1M, suggesting significant non-development related losses. Current assets plummeted 35% to just $1.5M while current liabilities of $7.1M create severe liquidity pressure and negative working capital of $5.6M. The combination of worsening losses, depleted cash resources, and negative stockholders' equity expanding to $8.2M signals potential going concern issues and imminent need for emergency financing.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-91.4%
-$13.7M-$26.3M

Net income declined 91.4% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
-64.2%
$31.0M$11.1M

R&D spending cut 64.2% — could signal cost discipline or concerning reduction in innovation investment.

Capital Expenditure
Cash Flow
-51.5%
$133K$64K

Capex reduced 51.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
+51.2%
-$53.6M-$26.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
-34.8%
$2.4M$1.5M

Current assets declined 34.8% — monitor working capital adequacy and short-term liquidity.

Interest Expense
P&L
-28.1%
$256K$184K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Assets
Balance Sheet
+26.6%
$3.5M$4.4M

Asset base grew 26.6% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+24.5%
$10.1M$12.6M

Liabilities increased 24.5% — monitor debt-to-equity ratio and interest coverage.

Stockholders Equity
Balance Sheet
-23.4%
-$6.7M-$8.2M

Equity decreased 23.4% — buybacks or losses reducing book value, monitor solvency ratios.

Current Liabilities
Balance Sheet
-21.8%
$9.0M$7.1M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-04-02
ADDED
We will require substantial additional financing to achieve our business objectives and to fund our operations.
We may not realize the benefits of any acquisitions, strategic alliances, or similar arrangements that we enter into.
If we fail to meet Nasdaq s continued listing requirements, our Common Stock and our outstanding public warrants to purchase Common Stock could be delisted We have previously failed to timely file certain periodic reports with the SEC and could fail to timely file such reports in the future.
We believe that sustainability and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative business models and engagement throughout various stages of the drug development and commercialization lifecycle.
We believe our precision T cell technology, ExacTcell TM , represents a significant scientific breakthrough with the potential to mainstream cell therapy with a new class of off-the-shelf pre-manufactured and ready-to-use allogeneic T cell therapies with diverse applications across virology, oncology, and other areas.
+7 more — sign up free →
REMOVED
We will require substantial additional financing to achieve our business objectives.
We have previously failed to timely file certain periodic reports with the SEC and could fail to timely file such reports in the future.
We believe that sustainability and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative business models and engagement across the development lifecycle and healthcare system.
We believe our allogeneic, precision T cell technology, ExacTcell TM , represents a significant scientific breakthrough with the potential to mainstream cell therapy with a new class of off-the-shelf manufactured and stored for immediate use T cell therapies with diverse applications across virology, oncology, and other areas.
We are focused on using ExacTcell to develop allogeneic therapeutics, meaning therapeutics that are intended to be infused in patients other than the original donor.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →